NDAORALCAPSULE
Approved
Mar 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZONEGRAN (zonisamide) by ANI Pharmaceuticals is carbonic anhydrase inhibitors [moa]. Approved for epilepsy, partial seizures. First approved in 2000.
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZONEGRAN (zonisamide) is an oral anti-epileptic agent approved in 2000 that functions as a carbonic anhydrase inhibitor. It is indicated for use in epilepsy management and is administered as a capsule formulation. The drug represents an established treatment option in the anticonvulsant landscape with multiple decades of clinical experience.
$0.0BPart D
Mechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Anti-epileptic Agent
Indications (2)
Clinical Trials (20)
Zonisamide Outpatient Study
Started Mar 2019
0Post Traumatic Stress DisorderAlcohol Use Disorder
Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence
Started Jun 2013
24 enrolled
Alcohol DependencePost-Traumatic Stress Disorder (PTSD)
A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
Started Mar 2012
104 enrolled
Partial Onset Seizures
A Study to Evaluate the Safety and Efficacy of Zonisamide an Antiepileptic Drug as Monotherapy or Adjunctive Therapy in Treatment of Adult Patients With Partial, Generalized or Combined Seizures.
Started Jan 2011
655 enrolled
Partial, Generalized and Combined Seizures
Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients
Started Mar 2010
50 enrolled
Sleep ApneaObstructive Sleep ApneaObesity
Worked on ZONEGRAN at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.